The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 27, 2026

Filed:

Aug. 18, 2023
Applicants:

The Government of the United States, As Represented BY the Secretary of the Army, Fort Detrick, MD (US);

Arcturus Therapeutics, Inc., San Diego, CA (US);

Inventors:

Jay W. Hooper, New Market, MD (US);

Eric M. Mucker, Thurmont, MD (US);

Padmanabh Chivukula, San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/39 (2006.01); A61K 39/12 (2006.01); A61K 39/275 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 39/12 (2013.01); A61K 39/275 (2013.01); C12N 7/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55511 (2013.01); C12N 2760/12134 (2013.01); C12N 2760/12171 (2013.01);
Abstract

A nucleic acid vaccine composition comprising one or more of a plasmid-based nucleic acid vaccine and immunotherapy, as well as a lipid formulation, is provided. In addition, the present invention provides a method of enhancing the potency of plasmid-based DNA vaccines and immunotherapies, by formulating a vaccine and/or immunotherapy in a lipid formulation, which is stable when refrigerated or stored frozen, is then delivered to a vaccinee by either needle/syringe, jet injection, or microneedles. The lipid formulation of the present invention comprises one or more lipid excipients selected from 1,2-Distearoyl-sn-glycero-3-phosphocholine, Cholest-5-en-3β-ol, 1,2-Dimyristoyl-rac-glycero-3-methylpolyoxyethlene, and or more symmetric ionizable cationic lipids. The present invention increases vaccine potency dramatically. It was unexpectedly discovered that the level of immunogen, or immune response molecules, produced in vivo is increased (versus administering merely the vaccine or immunotherapy) and, in the case of a vaccine immunogen, the immune response is enhanced.


Find Patent Forward Citations

Loading…